Faculty of Pharmaceutical Sciences (Rebić, Cragg, De Vera), University of British Columbia; Arthritis Research Canada (Rebić, De Vera); School of Population and Public Health (Cheng, Law); Centre for Health Services and Policy Research (Cheng, Law); Department of Obstetrics and Gynaecology (Brotto), University of British Columbia; Centre for Advancing Health Outcomes (De Vera), St. Paul's Hospital, Vancouver, BC.
Faculty of Pharmaceutical Sciences (Rebić, Cragg, De Vera), University of British Columbia; Arthritis Research Canada (Rebić, De Vera); School of Population and Public Health (Cheng, Law); Centre for Health Services and Policy Research (Cheng, Law); Department of Obstetrics and Gynaecology (Brotto), University of British Columbia; Centre for Advancing Health Outcomes (De Vera), St. Paul's Hospital, Vancouver, BC
CMAJ. 2024 Nov 24;196(40):E1331-E1340. doi: 10.1503/cmaj.241024.
In Canada, many patients face substantial out-of-pocket costs for prescription medication, which may affect their ability to take their medications as prescribed. We sought to conduct a comprehensive analysis of the burden and predictors of cost-related nonadherence in Canada.
Using pooled data from the 2015, 2016, 2018, 2019, and 2020 iterations of the Canadian Community Health Survey, we calculated weighted population estimates of the burden of cost-related nonadherence in the preceding 12 months and used logistic regression models to measure the association of 15 demographic, health, and health system predictors of cost-related nonadherence overall and stratified by sex.
We included 223 085 respondents. We found that 4.9% of respondents aged 12 years or older reported cost-related nonadherence. Those who self-identified as female, belonging to a racial or ethnic minority group, or bisexual, pansexual, or questioning were more likely to report cost-related nonadherence. Younger age, higher disease burden, poorer health, non-employer prescription drug coverage, and not living in the province of Quebec were associated with cost-related nonadherence.
Our nationally representative findings reveal inequities that disproportionally affect marginalized people at the intersections of sex, race, age, and disability, and vary by province. This foundational understanding of the state of cost-related nonadherence may be used to inform potential expansion of public drug coverage eligibility, premiums, and cost-sharing policies that address financial barriers to medication adherence.
在加拿大,许多患者需要承担高昂的处方药自付费用,这可能影响他们遵医嘱服药的能力。我们旨在对加拿大与费用相关的不依从的负担和预测因素进行全面分析。
使用加拿大社区健康调查 2015、2016、2018、2019 和 2020 年迭代的数据进行汇总,我们计算了过去 12 个月中与费用相关的不依从的负担的加权人口估计值,并使用逻辑回归模型衡量了 15 个人口统计学、健康和卫生系统预测因素对与费用相关的不依从的总体关联,以及按性别分层的关联。
我们纳入了 223085 名应答者。我们发现,12 岁及以上的应答者中有 4.9%报告了与费用相关的不依从。自我认同为女性、属于种族或少数民族群体、或为双性恋、泛性恋或质疑性别的人更有可能报告与费用相关的不依从。年龄较小、疾病负担较高、健康状况较差、无雇主处方药覆盖以及不住在魁北克省与与费用相关的不依从相关。
我们的全国代表性研究结果揭示了不平等现象,这些不平等现象不成比例地影响到处于性别、种族、年龄和残疾交叉点的边缘化人群,并因省份而异。对与费用相关的不依从的这种基本理解可用于为扩大公共药物覆盖范围的资格、保费和共付费用政策提供信息,这些政策可以解决药物依从性的经济障碍。